Researchers found that HIV-1 protease inhibitors like nelfinavir induce oxidative stress in pancreatic beta-cells, leading to decreased insulin secretion. Thymoquinone, an antioxidant from black seed oil, protects these cells by decreasing reactive oxygen species and increasing antioxidant levels.
Chronic ethanol feeding inhibits nuclear proteasome activity, altering epigenetic mechanisms and gene expression. Proteasome inhibition also affects the remethylation pathway, leading to decreased histone acetylation and increased betainehomocysteine methyltransferase (BHMT) enzyme.
This study investigates the efficacy of continuous regional arterial infusion (CRAI) using gabexate mesilate in treating severe acute pancreatitis. CRAI significantly reduced mortality rate and incidence of infectious complications compared to conventional systemic therapy.
Researchers at Scripps Florida have received a $1.5 million grant to develop novel drug targets for amebiasis and giardiasis, two serious water- and food-borne illnesses caused by microscopic parasites. The goal is to create small molecule inhibitors that target specific proteases playing a critical role in parasite lifecycle.
Researchers found that HIV protease inhibitors can decrease photoreceptor apoptosis in mouse models of retinal detachment. The study suggests that these drugs may prevent vision loss after retinal detachment by inhibiting mitochondrial apoptosis.
A new compound has been developed that targets the flap recognition pocket of the HIV-1 protease, inhibiting its activity. This mechanism is distinct from current protease inhibitors and holds promise for a new class of AIDS drugs with better drug-like properties.
Researchers found that HIV protease inhibitors block an enzyme crucial for generating the structural scaffolding of the cell nucleus. This leads to an accumulation of prelamin A and causes disease phenotypes similar to those associated with genetic defects in ZMPSTE24.
Researchers at the University of Pennsylvania have discovered a way to pre-screen cancer patients for blood cancer drugs by testing for p53, a tumor-suppressor protein. This test may help identify patients who are most likely to respond to treatment and avoid harmful side effects.
A 28-year study of Japanese-American men found that growing up in a large family or being born later in the family increased the risk of developing gastric adenocarcinoma. The results suggest that early-life social environment plays a significant role in microbially induced malignancies expressed decades later.
A combination of a nucleoside reverse transcriptase inhibitor and a protease inhibitor may prevent the negative cardiovascular effects of long-term protease inhibitor use, including hardening of the arteries. This could allow patients to take their medications without worrying about these side effects.
A preliminary study suggests that using a single boosted protease inhibitor instead of the standard regimen may be an effective treatment for select patients with HIV infection. The study found that 91% of participants experienced virologic success after 24 weeks of simplified therapy.
Researchers at Scripps Research Institute have identified a new class of potent SARS virus protease inhibitors, offering hope for developing a possible drug treatment against the disease. These benzotriazole esters block the enzyme and are stable enough to be used in clinical trials.
Researchers at HHMI used molecular dynamics simulations to identify a potential new drug target for treating HIV, which is often resistant to existing medications. The study focused on a rare strain of HIV with mutations that can evade commonly prescribed drugs.
A study of 626 patients found that Black patients on HAART had a lower risk of atheroma than White and Hispanic patients. Genetic variants were associated with dyslipidemia in Hispanic patients, but not in others.
Researchers discovered racial variations in lipid levels among HIV-1 patients on protease inhibitors, which may inform the development of tailored treatment plans. These findings could also lead to earlier initiation of lipid-modifying therapies for high-risk patients.
Researchers found that HIV protease inhibitors (PIs) can inhibit programmed cell death in mouse models with hepatitis, shock, and stroke. PIs maintain mitochondrial integrity to prevent apoptosis, suggesting potential uses for related compounds in non-HIV disorders.
New treatments for pediatric HIV infection were not always used as recommended by guidelines, with single and dual NRTI regimens being most frequent from 1987-1997. From 1998-2003, 22% of children initiated ART with unapproved regimens, and switching risk decreased with age but increased with year of initiation.
Researchers have discovered a potential link between protease inhibitor drugs and heart rhythm irregularities in HIV patients. The study, published in The Lancet, found that certain drug combinations could trigger adverse heart effects, highlighting the need for closer monitoring of vulnerable individuals.
Researchers found that HIV-1 protease inhibitors, such as saquinavir and ritonavir, effectively inhibit P. falciparum growth and demonstrate anti-malarial activity. The study builds on previous findings of antiretroviral agents reducing parasite adhesion to endothelial surfaces.
Researchers explored strategies to combat HIV-1 protease resistance, a key factor in treatment failure. The study identified novel approaches to inhibit the enzyme, offering potential solutions to overcome drug resistance and improve treatment outcomes.
Researchers have found that proteasome inhibitors can cause a model of Parkinson's disease in rats, mirroring symptoms such as slowness of movement and tremors. The study suggests that environmental factors, including exposure to toxins, may contribute to the development of Parkinson's.
The study found that boosting GW433908 with ritonavir reduced the incidence of PI-resistance selected by either the study PI or NRTIs ABC and 3TC. In contrast, unboosted 908 had a higher rate of resistance to 3TC and some patients developed mutations associated with APV resistance.
Researchers found that HIV protease inhibitors directly promote atherosclerosis in mice by inducing changes in macrophages. A commentary article proposes a mechanism and suggests ways to disrupt this process. The study has significant implications for the long-term use of these drugs in managing chronic HIV infection.
A phase II study of 100 patients with previously untreated HIV found that kaletra held the virus at undetectable levels for four years, with 72% maintaining suppressed viral loads. The results suggest that Kaletra remains a crucial option for initial therapy, helping to prolong time to resistance development.
Researchers found atazanavir significantly lowers total cholesterol, low-density lipoprotein (
Northwestern researcher Robert L. Murphy calls for simplified, less toxic HIV therapies due to complex regimens and adverse effects. He discusses potential new treatments like atazanavir, a single-daily-dose protease inhibitor with minimal side effects.
A new study published in The Lancet suggests that abacavir-containing regimens are more effective than zidovudine/lamivudine in children with HIV-1 who have not previously been treated. This finding could provide a good NRTI backbone for use with protease inhibitors and non-nucleoside reverse-transcriptase inhibitors.
Researchers develop innovative approach to treating psoriasis using a novel combination of therapies and biomarkers, offering new hope for patients suffering from the chronic skin condition.
Researchers have found that protease inhibitors used in AIDS treatment can lead to severe cardiovascular problems by accumulating a certain apolipoprotein in liver cells. This accumulation causes the liver cell to release excessive lipoprotein particles into the bloodstream, increasing the risk of heart disease.
Peptide-T, a synthetic compound, prevents HIV from entering healthy human cells by adhering to specific cellular receptors. This new mechanism of action offers an alternative to existing protease inhibitors, which can develop resistance and cause harmful side effects.
Agenerase ™ demonstrates promising once-daily dosing results, allowing for simplified HIV therapy. The amprenavir prodrug, VX-175, offers significant simplification of protease inhibitor-based treatment by enabling daily dosing of just two or three pills.
Scientists have developed a novel approach to inhibit protein kinase enzymes, which play a crucial role in triggering cancers, hardening of the arteries, and autoimmune diseases. The researchers' bisubstrate analogs effectively prevent these enzymes from working, offering a promising therapeutic strategy for various diseases.
A preliminary study found that combining Agenerase with low-dose ritonavir increases amprenavir plasma levels, potentially improving treatment goals. The study, conducted on PI-experienced patients, showed a significant increase in amprenavir concentrations when ritonavir was added.
A new UC Francisco study reveals a link between chronic use of protease inhibitors and the development of avascular necrosis (AVN) of the femoral head in HIV/AIDS patients. Early diagnosis can lead to effective treatment, but high-risk hip replacement surgery is associated with infection risk for these patients.
Researchers link HIV-protease inhibitors to increased diabetes risk due to impaired glucose storage, prompting reevaluation of screening methods and development of new treatments. Up to 83% of patients on the drugs develop excess belly fat and type 2 diabetes.
A study published in AIDS found an association between osteopenia and protease inhibitors, a class of medications used to treat HIV/AIDS. Researchers discovered that patients taking these medications were more likely to develop low bone-mineral density, which can lead to fractures.
Researchers found that 10% of HIV-infected individuals experience severe liver toxicity while taking antiretroviral drugs, with ritonavir being the worst offender. Doctors should monitor liver enzyme levels to ensure safe treatment.
Researchers identified a class of compounds that prevent HIV from infecting cells by blocking the viral entry into the cell. The discovery holds great promise for identifying a new class of oral drugs for treating HIV infection and AIDS.
A study reveals a dramatic rise in oral warts among HIV patients treated with protease inhibitors, which are effective against HIV. The researchers found that these warts were difficult to control and highly prone to recurrence, causing discomfort and affecting eating habits.
A new study by Emory researchers found that HIV patients treated with protease inhibitors are more likely to engage in risky sex, including inconsistent condom use. The study also reveals significant differences in condom use among men who had sex with men (MSM) and heterosexual men or women.
A team of researchers documented a case of transmission of protease-resistant HIV, which is resistant to six of the 11 approved HIV anti-retroviral drugs. The patient was infected through unprotected anal intercourse with a partner who had previously been treated with these drugs, highlighting the need for continued prevention efforts.
Studies reveal that patients are more likely to discontinue protease inhibitors due to side effects and complexity of dosing regimen. Additionally, certain groups such as women, minorities, and those with less education are underrepresented in receiving potent drug cocktails containing protease inhibitors.
A nationwide study found a significant decline in HIV-related deaths and opportunistic infections from 1994 to mid-1997, largely due to the use of combination antiretroviral therapy including protease inhibitors. Prescription rates for combination therapy increased dramatically during this period.
Phase II data reveals amprenavir's potent drug profile, with sustained antiviral effects seen in patients treated with two-drug combinations. The medication is currently being evaluated in pivotal Phase III clinical trials and has an expected US new drug application filing later in 1998.
Vanderbilt University Medical Center researchers found that a 'transporter molecule' called P-glyco protein may prevent protease inhibitors from reaching the virus, raising hope for boosting treatment effectiveness and reducing costs. The discovery could provide new strategies for treating HIV by targeting the protein's action.
A recent NIH study found that a combination of a protease inhibitor and two nucleoside analogue reverse transcriptase inhibitors can significantly reduce the occurrence of AIDS-defining illnesses or death. The study, ACTG 320, demonstrated improved survival and delayed disease progression in patients receiving triple combination therapy.